Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apabetalone for Pulmonary Arterial Hypertension
NCT04915300Phase 2Unknown
- Sponsor
- Université Laval
- Start
- Oct 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Apabetalone with Placebo (2 arms). Primary endpoint: Pulmonary Vascular Resistance at 24 weeks. Status: unknown.
02
Drugs
apabetalone
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT04915300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04915300.